NCT04299022View on ClinicalTrials.gov

Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care

RecruitingOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Fractures, BoneNonunion of FractureFractures, OpenFractures, UnunitedFracture, TibialFracture of FemurFracture Arm
Interventions
OTHER

Vivigen Cellular Bone Matrix

Allograft bone matrix

Trial Locations (4)

23507

RECRUITING

Sentara Hospitals, Norfolk

27710

RECRUITING

Duke University Medical Center, Durham

32806

RECRUITING

OrlandoHealth, Orlando

07302

NOT_YET_RECRUITING

RWJBarnabas Health, Jersey City

Sponsors

Lead Sponsor

LifeNet Health
All Listed Sponsors
lead

LifeNet Health

INDUSTRY

NCT04299022 - Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care | Biotech Hunter | Biotech Hunter